The role and optimal duration of beta-blocker therapy following myocardial infarction (MI) have been increasingly questioned in the contemporary era of advanced reperfusion strategies and secondary prevention therapies. In a recent study published in the New England Journal of Medicine, investigators evaluated the safety and clinical outcomes associated with discontinuation of long-term beta-blocker therapy in stable post-MI patients without clear ongoing indications such as heart failure or reduced left ventricular ejection fraction (LVEF).
This randomized clinical trial enrolled patients with a history of MI—typically at least 6 to 12 months prior—who were clinically stable and receiving chronic beta-blocker therapy. Participants were randomized to either continue or discontinue beta-blockers, with the primary endpoint defined as a composite of death, nonfatal MI, nonfatal stroke, or hospitalization for cardiovascular causes. The study was designed as a noninferiority trial to determine whether stopping therapy would not lead to worse outcomes compared with continuation.
Results showed that discontinuation of beta-blockers did not result in a statistically significant increase in major adverse cardiovascular events compared with continued therapy. However, the noninferiority criterion was not formally met, indicating some uncertainty in definitively concluding equivalence between the two strategies. Event rates were slightly higher in the discontinuation group, but the absolute differences were modest. Importantly, there was no meaningful improvement in quality of life among patients who stopped therapy, suggesting limited symptomatic benefit from discontinuation
These findings should be interpreted in the broader context of evolving evidence. Contemporary meta-analyses and randomized trials suggest that in patients with preserved LVEF (≥50%), beta-blockers may not significantly reduce mortality, recurrent MI, or heart failure risk after the acute phase of MI. This raises important questions about the necessity of lifelong beta-blocker therapy in low-risk populations.
In conclusion, while discontinuation of beta-blockers after MI appears relatively safe in carefully selected, stable patients without other indications, the lack of definitive noninferiority and absence of quality-of-life benefits warrant cautious, individualized decision-making. These results contribute to a growing paradigm shift toward more tailored secondary prevention strategies in post-MI care.
